3-{[(1R,2S,5S)-3-[(2S)-2-[(tert-butylcarbamoyl)amino]-3,3-dimethylbutanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2-yl]formamido}-4-cyclobutyl-2-oxobutanamide
| Title | Journal |
|---|---|
| Resistance Mechanisms in Hepatitis C Virus: implications for Direct-Acting Antiviral Use. | Drugs 20170701 |
| An update on the management of chronic hepatitis C: 2015 Consensus guidelines from the Canadian Association for the Study of the Liver. | Canadian journal of gastroenterology & hepatology 20150101 |
| A high-throughput, multiplexed assay for superfamily-wide profiling of enzyme activity. | Nature chemical biology 20140801 |
| The combination of alisporivir plus an NS5A inhibitor provides additive to synergistic anti-hepatitis C virus activity without detectable cross-resistance. | Antimicrobial agents and chemotherapy 20140601 |
| Discovery of ABT-267, a pan-genotypic inhibitor of HCV NS5A. | Journal of medicinal chemistry 20140313 |
| Highly efficient infectious cell culture of three hepatitis C virus genotype 2b strains and sensitivity to lead protease, nonstructural protein 5A, and polymerase inhibitors. | Hepatology (Baltimore, Md.) 20140201 |
| Azetidines and spiro azetidines as novel P2 units in hepatitis C virus NS3 protease inhibitors. | Bioorganic & medicinal chemistry letters 20131201 |
| In vitro efficacy of approved and experimental antivirals against novel genotype 3 hepatitis C virus subgenomic replicons. | Antiviral research 20131101 |
| Restoration of the activated Rig-I pathway in hepatitis C virus (HCV) replicon cells by HCV protease, polymerase, and NS5A inhibitors in vitro at clinically relevant concentrations. | Antimicrobial agents and chemotherapy 20130901 |
| Primuline derivatives that mimic RNA to stimulate hepatitis C virus NS3 helicase-catalyzed ATP hydrolysis. | The Journal of biological chemistry 20130705 |
| Analogs design, synthesis and biological evaluation of peptidomimetics with potential anti-HCV activity. | Bioorganic & medicinal chemistry 20130515 |
| Direct-acting antiviral agents for hepatitis C virus infection. | Annual review of pharmacology and toxicology 20130101 |
| Pharmacokinetic interaction between the hepatitis C virus protease inhibitor boceprevir and cyclosporine and tacrolimus in healthy volunteers. | Hepatology (Baltimore, Md.) 20121101 |
| Boceprevir: a protease inhibitor for the treatment of hepatitis C. | Clinical therapeutics 20121001 |
| Cost-effectiveness of boceprevir or telaprevir for untreated patients with genotype 1 chronic hepatitis C. | Hepatology (Baltimore, Md.) 20120901 |
| HIV-HCV co-infection facing HCV protease inhibitor licensing: implications for clinicians. | Liver international : official journal of the International Association for the Study of the Liver 20120901 |
| Factors that predict response of patients with hepatitis C virus infection to boceprevir. | Gastroenterology 20120901 |
| Protease inhibitors for the treatment of chronic hepatitis C genotype-1 infection: the new standard of care. | The Lancet. Infectious diseases 20120901 |
| Single-dose pharmacokinetics of boceprevir in subjects with impaired hepatic or renal function. | Clinical pharmacokinetics 20120901 |
| New pharmacotherapy for hepatitis C. | Clinical pharmacology and therapeutics 20120901 |
| Refinement of stopping rules during treatment of hepatitis C genotype 1 infection with boceprevir and peginterferon/ribavirin. | Hepatology (Baltimore, Md.) 20120801 |
| Telaprevir and boceprevir in African Americans with genotype 1 chronic hepatitis C: implications for patients and providers. | Southern medical journal 20120801 |
| HIV coinfection with hepatitis C virus: evolving epidemiology and treatment paradigms. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20120715 |
| Will IL28B polymorphism remain relevant in the era of direct-acting antiviral agents for hepatitis C virus? | Hepatology (Baltimore, Md.) 20120701 |
| Recent successes and noteworthy future prospects in the treatment of chronic hepatitis C. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20120701 |
| Hepatitis C virus treatment and liver transplantation in the era of new antiviral therapies. | Current opinion in organ transplantation 20120601 |
| Hepatitis drug reduces effects of HIV medications. | JAMA 20120523 |
| New genetic discoveries and treatment for hepatitis C. | JAMA 20120509 |
| Review and management of drug interactions with boceprevir and telaprevir. | Hepatology (Baltimore, Md.) 20120501 |
| [Use of boceprevir and telaprevir in patients with hepatitis C virus infection (practical considerations)]. | Gastroenterologia y hepatologia 20120501 |
| Hepatitis C and substance use: new treatments and novel approaches. | Current opinion in psychiatry 20120501 |
| A practical guide for the use of boceprevir and telaprevir for the treatment of hepatitis C. | Journal of viral hepatitis 20120501 |
| Hepatitis C therapy update. | Current opinion in gastroenterology 20120501 |
| New direct-acting antiviral agents for the treatment of hepatitis C virus infection and perspectives. | Gut 20120501 |
| Discovery of boceprevir, a direct-acting NS3/4A protease inhibitor for treatment of chronic hepatitis C infections. | Trends in pharmacological sciences 20120501 |
| Update on the management and treatment of hepatitis C virus infection: recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program Office. | The American journal of gastroenterology 20120501 |
| New virologic tools for management of chronic hepatitis B and C. | Gastroenterology 20120501 |
| Maximizing opportunities and avoiding mistakes in triple therapy for hepatitis C virus. | Gastroenterology 20120501 |
| Management of patients coinfected with HCV and HIV: a close look at the role for direct-acting antivirals. | Gastroenterology 20120501 |
| Genetic factors and hepatitis C virus infection. | Gastroenterology 20120501 |
| Targeted therapies for hepatitis C reach the clinic. | Chemistry & biology 20120420 |
| Discovery of novel urea-based hepatitis C protease inhibitors with high potency against protease-inhibitor-resistant mutants. | Journal of medicinal chemistry 20120412 |
| Efficient, chemoenzymatic process for manufacture of the Boceprevir bicyclic [3.1.0]proline intermediate based on amine oxidase-catalyzed desymmetrization. | Journal of the American Chemical Society 20120411 |
| Clinical relevance of detectable but not quantifiable hepatitis C virus RNA during boceprevir or telaprevir treatment. | Hepatology (Baltimore, Md.) 20120401 |
| Provisional guidance on the use of hepatitis C virus protease inhibitors for treatment of hepatitis C in HIV-infected persons. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20120401 |
| [Current indications for triple therapy in hepatitis C virus infection]. | Gastroenterologia y hepatologia 20120401 |
| Review of boceprevir and telaprevir for the treatment of chronic hepatitis C. | Canadian journal of gastroenterology = Journal canadien de gastroenterologie 20120401 |
| Boceprevir. | Prescrire international 20120401 |
| [Hungarian consensus guideline for the diagnosis and treatment of B, C, and D viral hepatitis]. | Orvosi hetilap 20120311 |
| Peptidomimetic escape mechanisms arise via genetic diversity in the ligand-binding site of the hepatitis C virus NS3/4A serine protease. | Gastroenterology 20120301 |
| UK consensus guidelines for the use of the protease inhibitors boceprevir and telaprevir in genotype 1 chronic hepatitis C infected patients. | Alimentary pharmacology & therapeutics 20120301 |
| New drugs 2012 part I. | Nursing 20120301 |
| Protease inhibitors: silver bullets for chronic hepatitis C infection? | Cleveland Clinic journal of medicine 20120301 |
| Boceprevir: an oral protease inhibitor for the treatment of chronic HCV infection. | Expert review of anti-infective therapy 20120301 |
| Does antiviral therapy reduce the risk of hepatocellular carcinoma in patients with chronic hepatitis C? | Minerva gastroenterologica e dietologica 20120301 |
| Annual drug update: 2011 in review. | The Nurse practitioner 20120212 |
| The critical role of medication adherence in the success of boceprevir and telaprevir in clinical practice. | Journal of hepatology 20120201 |
| Resistance-associated variants in chronic hepatitis C patients treated with protease inhibitors. | Current gastroenterology reports 20120201 |
| Phase III results of Boceprevir in treatment naïve patients with chronic hepatitis C genotype 1. | Liver international : official journal of the International Association for the Study of the Liver 20120201 |
| Boceprevir and telaprevir for the treatment of chronic hepatitis C: safety management in clinical practice. | Liver international : official journal of the International Association for the Study of the Liver 20120201 |
| Phase III results in Genotype 1 naïve patients: predictors of response with boceprevir and telaprevir combined with pegylated interferon and ribavirin. | Liver international : official journal of the International Association for the Study of the Liver 20120201 |
| Triple therapy with telaprevir: results in hepatitis C virus-genotype 1 infected relapsers and non-responders. | Liver international : official journal of the International Association for the Study of the Liver 20120201 |
| Triple therapy with boceprevir for HCV genotype 1 infection: phase III results in relapsers and nonresponders. | Liver international : official journal of the International Association for the Study of the Liver 20120201 |
| Triple therapy for HCV genotype 1 infection: telaprevir or boceprevir? | Liver international : official journal of the International Association for the Study of the Liver 20120201 |
| Triple combination treatment for chronic hepatitis C with protease inhibitors, pegylated interferon and ribavirin: 'lead-in or no lead-in'? | Liver international : official journal of the International Association for the Study of the Liver 20120201 |
| Direct acting antivirals for the treatment of chronic hepatitis C: one pill a day for tomorrow. | Liver international : official journal of the International Association for the Study of the Liver 20120201 |
| Future treatment of patients with HCV cirrhosis. | Liver international : official journal of the International Association for the Study of the Liver 20120201 |
| Hepatitis C virus treatment pre- and post-liver transplantation. | Liver international : official journal of the International Association for the Study of the Liver 20120201 |
| Hepatitis C virus-human immunodeficiency virus coinfection. | Liver international : official journal of the International Association for the Study of the Liver 20120201 |
| What's new in HCV genotype 2 treatment. | Liver international : official journal of the International Association for the Study of the Liver 20120201 |
| Treatment of patients with genotype 3 chronic hepatitis C--current and future therapies. | Liver international : official journal of the International Association for the Study of the Liver 20120201 |
| The future for the treatment of genotype 4 chronic hepatitis C. | Liver international : official journal of the International Association for the Study of the Liver 20120201 |
| Barriers to hepatitis C treatment. | Liver international : official journal of the International Association for the Study of the Liver 20120201 |
| Mutations selected in the hepatitis C virus NS3 protease domain during sequential treatment with boceprevir with and without pegylated interferon alfa-2b. | Journal of viral hepatitis 20120201 |
| Treatment failure with new hepatitis C drugs. | Expert opinion on pharmacotherapy 20120201 |
| Boceprevir: a novel NS3/4 protease inhibitor for the treatment of hepatitis C. | Pharmacotherapy 20120201 |
| Triple therapy for hepatitis C. | JAAPA : official journal of the American Academy of Physician Assistants 20120201 |
| Boceprevir and telaprevir in the management of hepatitis C virus-infected patients. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20120101 |
| [Boceprevir-benefit assessment by the Institute for Quality and Efficiency in Health Care (IQWiG) in accordance with § 35a SGB V (dosage evaluation)]. | Zeitschrift fur Gastroenterologie 20120101 |
| [Expert opinion on boceprevir- and telaprevir-based triple therapies of chronic hepatitis C]. | Zeitschrift fur Gastroenterologie 20120101 |
| New developments in HCV therapy. | Journal of viral hepatitis 20120101 |
| Boceprevir, telaprevir, and rilpivirine hydrochloride. | Journal of the American Pharmacists Association : JAPhA 20120101 |
| [Victrelis and Incivek against hepatitis C: some promising options]. | Perspective infirmiere : revue officielle de l'Ordre des infirmieres et infirmiers du Quebec 20120101 |
| Antiviral strategies in hepatitis C virus infection. | Journal of hepatology 20120101 |
| A review of drug interactions with boceprevir and telaprevir: implications for HIV and transplant patients. | Annals of hepatology 20120101 |
| Treatment of chronic hepatitis C genotype 1 with triple therapy comprising telaprevir or boceprevir. | Swiss medical weekly 20120101 |
| Advances in the treatment of hepatitis C virus infection. | Topics in antiviral medicine 20120101 |
| [Efficacy of triple therapy in patients with chronic hepatitis C not treated and patients previously treated ineffectively]. | Przeglad epidemiologiczny 20120101 |
| Hepatitis C in 2011: A new standard of care and the race towards IFN-free therapy. | Nature reviews. Gastroenterology & hepatology 20111220 |
| [Side-effects of pegylated interferon plus ribavirin therapy with or without protease inhibitor direct acting antiviral agents during treatment of chronic hepatitis C virus infection]. | Orvosi hetilap 20111211 |
| New HCV drugs trigger race for more tolerable therapies. | Nature medicine 20111206 |
| Analysis of long-term persistence of resistance mutations within the hepatitis C virus NS3 protease after treatment with telaprevir or boceprevir. | Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology 20111201 |
| Boceprevir. | Hepatology (Baltimore, Md.) 20111201 |
| Telaprevir for the treatment of chronic hepatitis C infection. | Expert review of anti-infective therapy 20111201 |
| A major advance in treating hepatitis C. | The Johns Hopkins medical letter health after 50 20111201 |
| Direct-acting antiviral (DAA) actions in treatment-naïve patients. | Clinics and research in hepatology and gastroenterology 20111201 |
| Antiviral activity of telaprevir and boceprevir for the treatment of hepatitis C virus infection in treatment-experienced patients. | Clinics and research in hepatology and gastroenterology 20111201 |
| New hepatitis C regimen stimulates changes in therapy management. | Managed care (Langhorne, Pa.) 20111201 |
| Challenges and opportunities for hepatitis C drug development in HIV-hepatitis C virus-co-infected patients. | AIDS (London, England) 20111128 |
| Protease inhibitors for treatment of genotype 1 hepatitis C virus infection. | BMJ (Clinical research ed.) 20111110 |
| New treatments for chronic hepatitis C virus infection. | Medecine et maladies infectieuses 20111101 |
| Future of hepatitis C therapy: development of direct-acting antivirals. | Current opinion in HIV and AIDS 20111101 |
| Directly acting antivirals for hepatitis C and antiretrovirals: potential for drug-drug interactions. | Current opinion in HIV and AIDS 20111101 |
| Formulary management of the protease inhibitors boceprevir and telaprevir for chronic hepatitis C virus. | Journal of managed care pharmacy : JMCP 20111101 |
| The expanding role of the pharmacist in the management of hepatitis C infection. | Journal of managed care pharmacy : JMCP 20111101 |
| An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. | Hepatology (Baltimore, Md.) 20111001 |
| Antiviral drugs for viruses other than human immunodeficiency virus. | Mayo Clinic proceedings 20111001 |
| Boceprevir. | Drugs of today (Barcelona, Spain : 1998) 20111001 |
| [New triple therapy in chronic hepatitis C. Increased patient chances]. | MMW Fortschritte der Medizin 20110929 |
| [New treatments for hepatitis C, which targets, what timeline?]. | Revue medicale suisse 20110907 |
| Differential efficacy of protease inhibitors against HCV genotypes 2a, 3a, 5a, and 6a NS3/4A protease recombinant viruses. | Gastroenterology 20110901 |
| Boceprevir: a protease inhibitor for the treatment of chronic hepatitis C. | The Annals of pharmacotherapy 20110901 |
| Emerging therapies in hepatitis C: dawn of the era of the direct-acting antivirals. | Gastroenterology clinics of North America 20110901 |
| Will direct-acting antivirals make a difference in HIV-HCV coinfected patients? | Expert review of anti-infective therapy 20110901 |
| Protease inhibitors in hepatitis C: from chronic disease to cure. | Irish medical journal 20110901 |
| Directly acting antivirals against hepatitis C virus. | The Journal of antimicrobial chemotherapy 20110801 |
| HCV protease inhibitors bring new options for patients. | American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20110801 |
| Going viral. | Scientific American 20110801 |
| An overview of emerging therapies for the treatment of chronic hepatitis C. | Clinics in liver disease 20110801 |
| Boceprevir: a user's guide. | Clinics in liver disease 20110801 |
| Second-wave protease inhibitors: choosing an heir. | Clinics in liver disease 20110801 |
| Telaprevir (Incivek) and boceprevir (Victrelis) for chronic hepatitis C. | The Medical letter on drugs and therapeutics 20110725 |
| [Studies with boceprevir]. | MMW Fortschritte der Medizin 20110721 |
| [A new era in therapy of hepatitis C: 'the therapy can now be individualized' (interview by Dr. med. Dirk Einecke)]. | MMW Fortschritte der Medizin 20110721 |
| Boceprevir for chronic HCV genotype 1 infection. | The New England journal of medicine 20110714 |
| Boceprevir for chronic HCV genotype 1 infection. | The New England journal of medicine 20110714 |
| New Merck and Vertex drugs raise standard of care in hepatitis C. | Nature biotechnology 20110711 |
| Hepatitis C virus resistance to protease inhibitors. | Journal of hepatology 20110701 |
| Two drugs approved for chronic hepatitis C infection. | American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20110701 |
| Telaprevir, boceprevir, cytochrome P450 and immunosuppressive agents--a potentially lethal cocktail. | Hepatology (Baltimore, Md.) 20110701 |
| Introduction: a smouldering public-health crisis. | Nature 20110608 |
| Therapeutics: new drugs hit the target. | Nature 20110608 |
| Perspective: miles to go before we sleep. | Nature 20110608 |
| Distributive justice and the arrival of direct-acting antivirals: who should be first in line? | Hepatology (Baltimore, Md.) 20110601 |
| FDA Advisory Committee reviews safety of boceprevir. | AIDS patient care and STDs 20110601 |
| [New therapeutic options in chronic hepatitis C virus infection]. | Orvosi hetilap 20110529 |
| Estimation of inhibitory quotient using a comparative equilibrium dialysis assay for prediction of viral response to hepatitis C virus inhibitors. | Journal of viral hepatitis 20110501 |
| A new standard of care for the treatment of chronic HCV infection. | Nature reviews. Gastroenterology & hepatology 20110501 |
| Viral hepatitis: progress and promise. | Nature reviews. Gastroenterology & hepatology 20110501 |
| Infectious diseases. First specific drugs raise hopes for hepatitis C. | Science (New York, N.Y.) 20110408 |
| Boceprevir for untreated chronic HCV genotype 1 infection. | The New England journal of medicine 20110331 |
| Boceprevir for previously treated chronic HCV genotype 1 infection. | The New England journal of medicine 20110331 |
| A new era of hepatitis C therapy begins. | The New England journal of medicine 20110331 |
| Characterization of human liver enzymes involved in the biotransformation of boceprevir, a hepatitis C virus protease inhibitor. | Drug metabolism and disposition: the biological fate of chemicals 20110301 |
| The results of Phase III clinical trials with telaprevir and boceprevir presented at the Liver Meeting 2010: a new standard of care for hepatitis C virus genotype 1 infection, but with issues still pending. | Gastroenterology 20110301 |
| Drugs in development for viral hepatitis: care and caution. | Drugs 20110212 |
| Big changes are coming in hepatitis C. | Current gastroenterology reports 20110201 |
| Hepatitis in 2010: the dawn of a new era in HCV therapy. | Nature reviews. Gastroenterology & hepatology 20110201 |
| [Future of antiviral therapy for chronic hepatitis C. Direct antiviral acting medications]. | Pharmazie in unserer Zeit 20110101 |
| The role of triple therapy with protease inhibitors in hepatitis C virus genotype 1 naïve patients. | Liver international : official journal of the International Association for the Study of the Liver 20110101 |
| The role of triple therapy in HCV genotype 1-experienced patients. | Liver international : official journal of the International Association for the Study of the Liver 20110101 |
| New direct-acting antivirals' combination for the treatment of chronic hepatitis C. | Liver international : official journal of the International Association for the Study of the Liver 20110101 |
| Impact of ribavirin on HCV replicon RNA decline during treatment with interferon-α and the protease inhibitors boceprevir or telaprevir. | Antiviral therapy 20110101 |
| New therapies for hepatitis C virus infection. | Missouri medicine 20110101 |
| Impact of HCV protease-inhibitor-based triple therapy for chronic HCV genotype 1 infection. | Antiviral therapy 20110101 |
| Hepatitis C therapy in 2011: is less more, is more less? | The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases 20110101 |
| IL28B polymorphism -- predictive factor of HCV infected genotype 1 individuals to treatment response and management of therapy. | Romanian journal of internal medicine = Revue roumaine de medecine interne 20110101 |
| Susceptibility of treatment-naive hepatitis C virus (HCV) clinical isolates to HCV protease inhibitors. | Antimicrobial agents and chemotherapy 20101201 |
| Comparison of the Mechanisms of Drug Resistance among HIV, Hepatitis B, and Hepatitis C. | Viruses 20101201 |
| Preclinical characterization of BI 201335, a C-terminal carboxylic acid inhibitor of the hepatitis C virus NS3-NS4A protease. | Antimicrobial agents and chemotherapy 20101101 |
| Boceprevir. | Drugs in R&D 20100901 |
| STAT-C: a full revolution or just a step forward? | Lancet (London, England) 20100828 |
| Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. | Lancet (London, England) 20100828 |
| Hepatitis C Virus NS3/4A Protease Inhibitors: A Light at the End of the Tunnel. | Viruses 20100801 |
| Improved P2 phenylglycine-based hepatitis C virus NS3 protease inhibitors with alkenylic prime-side substituents. | Bioorganic & medicinal chemistry 20100715 |
| The hepatitis C virus (HCV) NS4B RNA binding inhibitor clemizole is highly synergistic with HCV protease inhibitors. | The Journal of infectious diseases 20100701 |
| Excitement grows for potential revolution in hepatitis C virus treatment. | Nature reviews. Drug discovery 20100701 |
| Preclinical characterization of the antiviral activity of SCH 900518 (narlaprevir), a novel mechanism-based inhibitor of hepatitis C virus NS3 protease. | Antimicrobial agents and chemotherapy 20100601 |
| New directly acting antivirals for hepatitis C: potential for interaction with antiretrovirals. | The Journal of antimicrobial chemotherapy 20100601 |
| In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435. | Antimicrobial agents and chemotherapy 20100501 |
| Cyclic sulfones as novel P3-caps for hepatitis C virus NS3/4A (HCV NS3/4A) protease inhibitors: synthesis and evaluation of inhibitors with improved potency and pharmacokinetic profiles. | Journal of medicinal chemistry 20100422 |
| The introduction of P4 substituted 1-methylcyclohexyl groups into Boceprevir: a change in direction in the search for a second generation HCV NS3 protease inhibitor. | Bioorganic & medicinal chemistry letters 20100415 |
| Potent ketoamide inhibitors of HCV NS3 protease derived from quaternized P1 groups. | Bioorganic & medicinal chemistry letters 20100401 |
| Towards the second generation of Boceprevir: Dithianes as an alternative P2 substituent for 2,2-dimethyl cycloproyl proline in HCV NS3 protease inhibitors. | Bioorganic & medicinal chemistry letters 20100301 |
| Discovery of potent sulfonamide P4-capped ketoamide second generation inhibitors of hepatitis C virus NS3 serine protease with favorable pharmacokinetic profiles in preclinical species. | Bioorganic & medicinal chemistry 20100301 |
| Activity of aminocandin (IP960; HMR3270) compared with amphotericin B, itraconazole, caspofungin and micafungin in neutropenic murine models of disseminated infection caused by itraconazole-susceptible and -resistant strains of Aspergillus fumigatus. | International journal of antimicrobial agents 20100201 |
| P4 capped amides and lactams as HCV NS3 protease inhibitors with improved potency and DMPK profile. | Bioorganic & medicinal chemistry letters 20100115 |
| MK-7009, a potent and selective inhibitor of hepatitis C virus NS3/4A protease. | Antimicrobial agents and chemotherapy 20100101 |
| Advances in the development of macrocyclic inhibitors of hepatitis C virus NS3-4A protease. | Current topics in medicinal chemistry 20100101 |
| On the cusp of change: new therapeutic modalities for HCV. | Annals of hepatology 20100101 |
| Medicinial chemistry. Preface. | Progress in medicinal chemistry 20100101 |
| The Journey to the Discovery of Boceprevir: an NS3-NS4 HCV protease inhibitor for the treatment of chronic hepatitis C. | Progress in medicinal chemistry 20100101 |
| Prompt arrival of antivirals against hepatitis C for HIV patients. | AIDS reviews 20100101 |
| Treatment of hepatitis C in 2011. | Journal of Ayub Medical College, Abbottabad : JAMC 20100101 |
| Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients. | Hepatology (Baltimore, Md.) 20091201 |
| Highly sensitive determination of HCV protease inhibitors boceprevir (SCH 503034) and telaprevir (VX 950) in human plasma by LC-MS/MS. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20091201 |
| A novel HCV NS3 protease mutation selected by combination treatment of the protease inhibitor boceprevir and NS5B polymerase inhibitors. | Antiviral research 20091101 |
| [New antiviral agents against hepatitis C in clinical trials. Hope for a cure--but resistance problems must be overcomed]. | Lakartidningen 20091101 |
| HCV-NS3 inhibitors: determination of their kinetic parameters and mechanism. | Biochimica et biophysica acta 20091001 |
| Hepatitis C drug development at a crossroads. | Hepatology (Baltimore, Md.) 20091001 |
| Potent aza-peptide derived inhibitors of HCV NS3 protease. | Bioorganic & medicinal chemistry letters 20090815 |
| Boceprevir, an NS3 protease inhibitor of HCV. | Clinics in liver disease 20090801 |
| Discovery of novel P3 sulfonamide-capped inhibitors of HCV NS3 protease. Inhibitors with improved cellular potencies. | Bioorganic & medicinal chemistry 20090701 |
| Toward the back-up of boceprevir (SCH 503034): discovery of new extended P4-capped ketoamide inhibitors of hepatitis C virus NS3 serine protease with improved potency and pharmacokinetic profiles. | Journal of medicinal chemistry 20090625 |
| Toward second generation hepatitis C virus NS3 serine protease inhibitors: discovery of novel P4 modified analogues with improved potency and pharmacokinetic profile. | Journal of medicinal chemistry 20090514 |
| Substituted imidazopyridines as potent inhibitors of HCV replication. | Journal of hepatology 20090501 |
| Inhibitors of hepatitis C virus NS3/4A: alpha-ketoamide based macrocyclic inhibitors. | Bioorganic & medicinal chemistry letters 20090415 |
| [Novel treatment for chronic hepatitis C in near future]. | Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology 20090401 |
| Second-generation highly potent and selective inhibitors of the hepatitis C virus NS3 serine protease. | Journal of medicinal chemistry 20090312 |
| Novel potent inhibitors of hepatitis C virus (HCV) NS3 protease with cyclic sulfonyl P3 cappings. | Bioorganic & medicinal chemistry letters 20090215 |
| Design, synthesis, and evaluation of oxygen-containing macrocyclic peptidomimetics as inhibitors of HCV NS3 protease. | Journal of medicinal chemistry 20090212 |
| Treatment of chronic hepatitis C: anticipated impact of resistance in patients treated with protease inhibitors. | Current gastroenterology reports 20090201 |
| Boceprevir, an NS3 serine protease inhibitor of hepatitis C virus, for the treatment of HCV infection. | Current opinion in investigational drugs (London, England : 2000) 20090201 |
| Discovery and structure-activity relationship of P1-P3 ketoamide derived macrocyclic inhibitors of hepatitis C virus NS3 protease. | Journal of medicinal chemistry 20090122 |
| Potent inhibitors of HCV-NS3 protease derived from boronic acids. | Bioorganic & medicinal chemistry letters 20090101 |
| Preclinical characteristics of the hepatitis C virus NS3/4A protease inhibitor ITMN-191 (R7227). | Antimicrobial agents and chemotherapy 20081201 |
| Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naïve patients. | Hepatology (Baltimore, Md.) 20081201 |
| Analysis of HCV resistance mutations during combination therapy with protease inhibitor boceprevir and PEG-IFN alpha-2b using TaqMan mismatch amplification mutation assay. | Journal of virological methods 20081101 |
| Hepatitis C Virus NS3/4A Protease Inhibitors. | Recent patents on anti-infective drug discovery 20081101 |
| Hepatitis C virus NS3-4A serine protease inhibitors: SAR of new P1 derivatives of SCH 503034. | Bioorganic & medicinal chemistry letters 20080715 |
| [The 43rd Annual Meeting of the European Association for the Study of the Liver (EASL), Milan, Italy, April 23-27, 2008]. | Orvosi hetilap 20080713 |
| Hepatitis C protease and polymerase inhibitors in development. | AIDS patient care and STDs 20080601 |
| Key steps in the structure-based optimization of the hepatitis C virus NS3/4A protease inhibitor SCH503034. | Journal of synchrotron radiation 20080501 |
| Hepatitis C virus NS3 protease inhibitors comprising a novel aromatic P1 moiety. | Bioorganic & medicinal chemistry 20080315 |
| Characterization of resistance mutations against HCV ketoamide protease inhibitors. | Antiviral research 20080301 |
| Potent and selective small molecule NS3 serine protease inhibitors of Hepatitis C virus with dichlorocyclopropylproline as P2 residue. | Bioorganic & medicinal chemistry 20080215 |
| Naturally occurring NS3-protease-inhibitor resistant mutant A156T in the liver of an untreated chronic hepatitis C patient. | Virology 20080120 |
| Challenges in modern drug discovery: a case study of boceprevir, an HCV protease inhibitor for the treatment of hepatitis C virus infection. | Accounts of chemical research 20080101 |
| Mapping natural polymorphisms of hepatitis C virus NS3/4A protease and antiviral resistance to inhibitors in worldwide isolates. | Antiviral therapy 20080101 |
| Future treatment options for HCV: double, triple, what is the optimal combination? | Best practice & research. Clinical gastroenterology 20080101 |
| Ultra-performance liquid chromatography/tandem mass spectrometric determination of diastereomers of SCH 503034 in monkey plasma. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20070601 |
| Discovery of the HCV NS3/4A protease inhibitor (1R,5S)-N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-3- [2(S)-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]- 6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide (Sch 503034) II. Key steps in structure-based optimization. | Journal of medicinal chemistry 20070517 |
| SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alpha-2b for genotype 1 nonresponders. | Gastroenterology 20070401 |
| Treatment of hepatitis C: don't put all your eggs in one basket! | Gastroenterology 20070401 |
| Specific targeted antiviral therapy for hepatitis C. | Current gastroenterology reports 20070301 |
| [Drugs for hepatitis B and C infection]. | Nihon rinsho. Japanese journal of clinical medicine 20070227 |
| Pharmacokinetic enhancement of the hepatitis C virus protease inhibitors VX-950 and SCH 503034 by co-dosing with ritonavir. | Antiviral chemistry & chemotherapy 20070101 |
| Discovery of (1R,5S)-N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]- 3-[2(S)-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]- 6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide (SCH 503034), a selective, potent, orally bioavailable hepatitis C virus NS3 protease inhibitor: a potential therapeutic agent for the treatment of hepatitis C infection. | Journal of medicinal chemistry 20061005 |
| Identification and analysis of fitness of resistance mutations against the HCV protease inhibitor SCH 503034. | Antiviral research 20060601 |
| SCH 503034, a mechanism-based inhibitor of hepatitis C virus NS3 protease, suppresses polyprotein maturation and enhances the antiviral activity of alpha interferon in replicon cells. | Antimicrobial agents and chemotherapy 20060301 |